Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19:37–50.

Article  CAS  PubMed  Google Scholar 

Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, et al. Pembrolizumab Plus Ipilimumab or Placebo for metastatic non-small-cell lung Cancer with PD-L1 tumor proportion score ≥ 50%: Randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 2021;39:2327–38.

Article  CAS  PubMed  Google Scholar 

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in Non-Small Cell Lung Cancer: facts and hopes. Clin Cancer Res. 2019;25:4592–602.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Pang K, Shi ZD, Wei LY, Dong Y, Ma YY, Wang W, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updat. 2023;66:100907.

Article  CAS  PubMed  Google Scholar 

Zhou K, Li S, Zhao Y, Cheng K. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer. Front Immunol. 2023;14:1127071.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Tao S, Liang S, Zeng T, Yin D. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Front Immunol. 2022;13:1043667.

Article  CAS  PubMed  Google Scholar 

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA Class I Antigen Processing and Presentation as a mechanism of Acquired Resistance to Immune checkpoint inhibitors in Lung Cancer. Cancer Discov. 2017;7:1420–35.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomed Pharmacother. 2022;156:113906.

Article  CAS  PubMed  Google Scholar 

Xiao G, Li L, Tanzhu G, Liu Z, Gao X, Wan X et al. Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. J Immunother Cancer. 2023;11.

Li H, Zhao A, Li M, Shi L, Han Q, Hou Z. Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy. Front Immunol. 2022;13:1046755.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Zhang E, Ding C, Li S, Zhou X, Aikemu B, Fan X, et al. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomark Res. 2023;11:28.

Article  PubMed Central  PubMed  Google Scholar 

Wang D, Wang J, Zhou D, Wu Z, Liu W, Chen Y et al. SWI/SNF complex genomic alterations as a predictive biomarker for response to immune checkpoint inhibitors in multiple cancers. Cancer Immunol Res. 2023.

Wildsmith S, Li W, Wu S, Stewart R, Morsli N, Raja R et al. Tumor Mutational Burden as a predictor of Survival with Durvalumab and/or Tremelimumab Treatment in recurrent or metastatic Head and Neck squamous cell carcinoma. Clin Cancer Res. 2023.

Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.

Article  PubMed Central  PubMed  Google Scholar 

Chu X, Niu L, Xiao G, Peng H, Deng F, Liu Z, et al. The long-term and short-term efficacy of Immunotherapy in Non-Small Cell Lung Cancer patients with brain metastases: a systematic review and Meta-analysis. Front Immunol. 2022;13:875488.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, et al. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep. 2023;5:100620.

Article  PubMed  Google Scholar 

Ziegler AE, Fittje P, Müller LM, Ahrenstorf AE, Hagemann K, Hagen SH, et al. The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56(bright) NK cells. Front Immunol. 2023;14:1117320.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Wegrzyn AS, Kedzierska AE, Obojski A. Identification and classification of distinct surface markers of T regulatory cells. Front Immunol. 2022;13:1055805.

Article  CAS  PubMed  Google Scholar 

Hartigan CR, Tong KP, Liu D, Laurie SJ, Ford ML. TIGIT agonism alleviates costimulation blockade-resistant rejection in a regulatory T cell-dependent manner. Am J Transplant. 2023;23:180–9.

Article  PubMed  Google Scholar 

Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, et al. The single-cell Landscape of Intratumoral Heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast Cancer. Adv Sci (Weinh). 2023;10:e2203699.

Article  PubMed  Google Scholar 

Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106:17858–63.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125:2046–58.

Article  PubMed Central  PubMed  Google Scholar 

Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O’Gorman WE et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity. 2022;55:512 – 26.e9.

Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23:781–92.

Article  CAS  PubMed  Google Scholar 

Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57.

Article  CAS  PubMed  Google Scholar 

Yeo J, Ko M, Lee DH, Park Y, Jin HS. TIGIT/CD226 Axis regulates Anti-Tumor Immunity. Pharmaceuticals (Basel). 2021;14.

Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022;10.

Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923–37.

Article  CAS  PubMed  Google Scholar 

Ostroumov D, Duong S, Wingerath J, Woller N, Manns MP, Timrott K, et al. Transcriptome profiling identifies TIGIT as a marker of T-Cell exhaustion in Liver Cancer. Hepatology. 2021;73:1399–418.

Article  CAS  PubMed  Google Scholar 

Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol.15:486–99.

Scott AC, Dundar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571:270–4.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, et al. Eomes(+)T-bet(low) CD8(+) T cells are functionally impaired and are Associated with poor clinical outcome in patients with Acute myeloid leukemia. Cancer Res. 2019;79:1635–45.

Article  CAS  PubMed  Google Scholar 

Wang F, Hou H, Wu S, Tang Q, Liu W, Huang M et al. TIGIT expression levels on human NK cells correlate with functional he terogeneity among healthy individuals. Eur J Immunol.45:2886–97.

Liu S, Zhang H, Li M, Hu D, Li C, Ge B, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 2013;20:456–64.

Article  CAS  PubMed  Google Scholar 

Li M, Xia P, Du Y, Liu S, Huang G, Chen J et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus rece ptor (PVR) ligand engagement suppresses interferon-γ production of nat ural killer cells via β-arrestin 2-mediated negative signaling. J Biol Chem.289:17647–57.

Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186:1338–42.

Article  CAS  PubMed  Google Scholar 

Li K, Yuan Z, Lyu J, Ahn E, Davis SJ, Ahmed R, et al. PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. Nat Commun. 2021;12:2746.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Calvet-Mirabent M, Sánchez-Cerrillo I, Martín-Cófreces N, Martínez-Fleta P, de la Fuente H, Tsukalov I, et al. Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8 + T cells in people living with HIV. EBioMedicine. 2022;81:104090.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Fathi M, Bahmanpour S, Barshidi A, Rasouli H, Karoon Kiani F, Mahmoud Salehi Khesht A, et al. Simultaneous blockade of TIGIT and HIF-1α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells. Int Immunopharmacol. 2021;101:108288.

Article  CAS  PubMed  Google Scholar 

Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4:573–81.

Article  CAS  PubMed  Google Scholar 

Ramsbottom KM, Hawkins ED, Shimoni R, McGrath M, Chan CJ, Russell SM, et al. Cutting edge: DNAX accessory molecule 1-deficient CD8 + T cells display immunological synapse defects that impair antitumor immunity. J Immunol. 2014;192:553–7.

Article  CAS  PubMed